Literature DB >> 27254113

Missing Data in Alcohol Clinical Trials with Binary Outcomes.

Kevin A Hallgren1, Katie Witkiewitz2, Henry R Kranzler3,4, Daniel E Falk5, Raye Z Litten5, Stephanie S O'Malley6, Raymond F Anton7.   

Abstract

BACKGROUND: Missing data are common in alcohol clinical trials for both continuous and binary end points. Approaches to handle missing data have been explored for continuous outcomes, yet no studies have compared missing data approaches for binary outcomes (e.g., abstinence, no heavy drinking days). This study compares approaches to modeling binary outcomes with missing data in the COMBINE study.
METHODS: We included participants in the COMBINE study who had complete drinking data during treatment and who were assigned to active medication or placebo conditions (N = 1,146). Using simulation methods, missing data were introduced under common scenarios with varying sample sizes and amounts of missing data. Logistic regression was used to estimate the effect of naltrexone (vs. placebo) in predicting any drinking and any heavy drinking outcomes at the end of treatment using 4 analytic approaches: complete case analysis (CCA), last observation carried forward (LOCF), the worst case scenario (WCS) of missing equals any drinking or heavy drinking, and multiple imputation (MI). In separate analyses, these approaches were compared when drinking data were manually deleted for those participants who discontinued treatment but continued to provide drinking data.
RESULTS: WCS produced the greatest amount of bias in treatment effect estimates. MI usually yielded less biased estimates than WCS and CCA in the simulated data and performed considerably better than LOCF when estimating treatment effects among individuals who discontinued treatment.
CONCLUSIONS: Missing data can introduce bias in treatment effect estimates in alcohol clinical trials. Researchers should utilize modern missing data methods, including MI, and avoid WCS and CCA when analyzing binary alcohol clinical trial outcomes.
Copyright © 2016 by the Research Society on Alcoholism.

Entities:  

Keywords:  Alcohol Clinical Trials; Missing Data; Multiple Imputation; Naltrexone; Simulation Study

Mesh:

Year:  2016        PMID: 27254113      PMCID: PMC5522809          DOI: 10.1111/acer.13106

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  23 in total

1.  Model misspecification sensitivity analysis in estimating causal effects of interventions with non-compliance.

Authors:  Booil Jo
Journal:  Stat Med       Date:  2002-11-15       Impact factor: 2.373

2.  Reasons for dropout from drug abuse treatment: symptoms, personality, and motivation.

Authors:  Samuel A Ball; Kathleen M Carroll; Monica Canning-Ball; Bruce J Rounsaville
Journal:  Addict Behav       Date:  2005-06-17       Impact factor: 3.913

3.  MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets.

Authors:  Ohidul Siddiqui; H M James Hung; Robert O'Neill
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

4.  A multiple-imputation-based approach to sensitivity analyses and effectiveness assessments in longitudinal clinical trials.

Authors:  Birhanu Teshome Ayele; Ilya Lipkovich; Geert Molenberghs; Craig H Mallinckrodt
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

5.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

6.  Substance user treatment dropout from client and clinician perspectives: a pilot study.

Authors:  Rebekka S Palmer; Mary K Murphy; Alessandro Piselli; Samuel A Ball
Journal:  Subst Use Misuse       Date:  2009       Impact factor: 2.164

Review 7.  Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders.

Authors:  Katie Witkiewitz; John W Finney; Alex H S Harris; Daniel R Kivlahan; Henry R Kranzler
Journal:  Alcohol Clin Exp Res       Date:  2015-08-06       Impact factor: 3.455

8.  Gabapentin treatment for alcohol dependence: a randomized clinical trial.

Authors:  Barbara J Mason; Susan Quello; Vivian Goodell; Farhad Shadan; Mark Kyle; Adnan Begovic
Journal:  JAMA Intern Med       Date:  2014-01       Impact factor: 21.873

9.  A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder.

Authors:  Janet Witte; Kate Bentley; Anne Eden Evins; Alisabet J Clain; Lee Baer; Paola Pedrelli; Maurizio Fava; David Mischoulon
Journal:  J Clin Psychopharmacol       Date:  2012-12       Impact factor: 3.153

10.  Imputation strategies for missing binary outcomes in cluster randomized trials.

Authors:  Jinhui Ma; Noori Akhtar-Danesh; Lisa Dolovich; Lehana Thabane
Journal:  BMC Med Res Methodol       Date:  2011-02-16       Impact factor: 4.615

View more
  12 in total

1.  Predictors and Outcomes of Twelve-Step Sponsorship of Stimulant Users: Secondary Analyses of a Multisite Randomized Clinical Trial.

Authors:  Dennis C Wendt; Kevin A Hallgren; Dennis C Daley; Dennis M Donovan
Journal:  J Stud Alcohol Drugs       Date:  2017-03       Impact factor: 2.582

2.  Results of Database Studies in Spine Surgery Can Be Influenced by Missing Data.

Authors:  Bryce A Basques; Ryan P McLynn; Michael P Fice; Andre M Samuel; Adam M Lukasiewicz; Daniel D Bohl; Junyoung Ahn; Kern Singh; Jonathan N Grauer
Journal:  Clin Orthop Relat Res       Date:  2017-12       Impact factor: 4.176

3.  World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom.

Authors:  Katie Witkiewitz; Nick Heather; Daniel E Falk; Raye Z Litten; Deborah S Hasin; Henry R Kranzler; Karl F Mann; Stephanie S O'Malley; Raymond F Anton
Journal:  Addiction       Date:  2020-03-10       Impact factor: 6.526

4.  Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.

Authors:  Matthew J Worley; Keith G Heinzerling; Steven Shoptaw; Walter Ling
Journal:  Addiction       Date:  2017-02-28       Impact factor: 6.526

5.  Prediction of Suicide Ideation and Attempt Among Substance-Using Patients in Primary Care.

Authors:  Kevin A Hallgren; Richard K Ries; David C Atkins; Kristin Bumgardner; Peter Roy-Byrne
Journal:  J Am Board Fam Med       Date:  2017 Mar-Apr       Impact factor: 2.657

6.  Tdap Vaccination Among Healthcare Personnel, Internet Panel Survey, 2012-2014.

Authors:  Anup Srivastav; Carla L Black; Peng-Jun Lu; Jun Zhang; Jennifer L Liang; Stacie M Greby
Journal:  Am J Prev Med       Date:  2017-05-23       Impact factor: 5.043

Review 7.  A Meta-Regression of Trial Features Predicting the Effects of Alcohol Use Disorder Pharmacotherapies on Drinking Outcomes in Randomized Clinical Trials: A Secondary Data Analysis.

Authors:  Erica N Grodin; Suzanna Donato; Han Du; ReJoyce Green; Spencer Bujarski; Lara A Ray
Journal:  Alcohol Alcohol       Date:  2022-09-10       Impact factor: 3.913

8.  A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.

Authors:  David Farabee; Timothy Condon; Kevin A Hallgren; Barbara McCrady
Journal:  J Subst Abuse Treat       Date:  2020-07-06

9.  Validity and measurement invariance of the Addictions Neuroclinical Assessment incentive salience domain among treatment-seekers with alcohol use disorder.

Authors:  Elena R Stein; Victoria R Votaw; Julia E Swan; Katie Witkiewitz
Journal:  J Subst Abuse Treat       Date:  2020-12-03

10.  Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.

Authors:  Daniel E Falk; Stephanie S O'Malley; Katie Witkiewitz; Raymond F Anton; Raye Z Litten; Megan Slater; Henry R Kranzler; Karl F Mann; Deborah S Hasin; Bankole Johnson; Didier Meulien; Megan Ryan; Joanne Fertig
Journal:  JAMA Psychiatry       Date:  2019-04-01       Impact factor: 25.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.